Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q1 2016 · 10-Q
Revenue—
Net Income-$29.52M-$29.52MN/M vs Q1 2015 EPS Diluted-$19.23-$19.23N/M vs Q1 2015 Operating Income-$1,821,100N/M Operating Cash Flow-$823,300N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Jun 30, 2015 · filed Aug 14, 2015 · 45 d after period end